-+ 0.00%
-+ 0.00%
-+ 0.00%

ENVISAGENICS AND BOEHRINGER INGELHEIM ENTER MULTI-TARGET COLLABORATION TO DEVELOP FIRST-IN-CLASS PRECISION THERAPIES BASED ON RNA SPLICING-DERIVED TARGETS FOR HARD-TO-TREAT CANCERS

Reuters·09/22/2026 12:07:03

Veuillez vous connecter pour afficher les détails des actualités